The team at Taylor Wessing LLP houses a team which exhibits broad expertise spanning venture capital transactions within the biotech space, medical device certifications, and data privacy issues. Practice head Alison Dennis utilises her broad expertise in IP and contractual matters to advise medium to large medical device and pharmaceutical manufacturers on commercialisation issues. Ross McNaughton handles the biotech side of the practice, predominantly assisting clients with issues surrounding international expansion and capital raising. With longstanding experience in biologics and small-molecule therapeutics, Adrian Toutoungi is particularly adept at advising clients on collaboration agreements, while Colin McCall assists clients with licensing agreements and R&D projects. Tasmina Goraya primarily focuses on arbitrations and regulatory disputes, in addition to clinical trial agreements.
Key clients
- Apollo Therapeutics
- Shield Therapeutics
- Pacira Biosciences
- Bracco Imagining
- Cambridge Cognition
- IP Group
- iRhythm Technologies
- Azenta
- Cambridge Epigenetix
- Sight Sciences
- Nuclera Nucleics Ltd
- PLACID0
- Theramex
- Abbott
- Pfizer
- Fusion Antibodies
Work highlights
- Advised Shield Therapeutics plc on three simultaneous complex transactions including its transformational collaboration agreement with NASDAQ-listed global healthcare company Viatris Inc.
- Advised Apollo Therapeutics on its license agreement with Nasdaq listed Avalo Therapeutics under which Apollo was granted rights to Avalo’s anti-IL-18 monoclonal antibody product AVTX-007 (camoteskimab).
- Advised Nuclera Nucleics on its Series B financing which brings the total raised to $58m. Nuclera will use the additional investments to accelerate the commercial launch of its eProtein desktop bioprinter.
Lawyers
Practice head
The lawyer(s) leading their teams.
Alison Dennis